Difference between revisions of "Strep. Groups A, B, C, G"

(Antibiotic SensitivitiesSanford Guide to Antimicrobial Therapy 2010)
(Antibiotic SensitivitiesSanford Guide to Antimicrobial Therapy 2010)
Line 30: Line 30:
 
| ||Pip-Taxo||+
 
| ||Pip-Taxo||+
 
|-
 
|-
| Carbapenems||Piperacillin||+
+
| [[Carbapenems]]||Piperacillin||+
 
|-
 
|-
 
| ||Doripenem||+
 
| ||Doripenem||+
Line 42: Line 42:
 
| ||[[Aztreonam[[||0
 
| ||[[Aztreonam[[||0
 
|-
 
|-
| Fluroquinolones||Ciprofloxacin||+/-
+
| [[Fluroquinolones]]||Ciprofloxacin||+/-
 
|-
 
|-
 
| ||Ofloxacin||+/-
 
| ||Ofloxacin||+/-
Line 56: Line 56:
 
| ||Gatifloxacin||+
 
| ||Gatifloxacin||+
 
|-
 
|-
| 1st G Cephalo||Cefazolin||+
+
| 1st G [[Cephalosporin]]||Cefazolin||+
 
|-
 
|-
| 2nd G. Ceph||Cefotetan||+
+
| 2nd G. [[Cephalosporin]]||Cefotetan||+
 
|-
 
|-
 
| ||Cefoxitin||+
 
| ||Cefoxitin||+
Line 64: Line 64:
 
| ||Cefuroxime||+
 
| ||Cefuroxime||+
 
|-
 
|-
| 3rd/4th G. Ceph||Cefotaxime||+
+
| 3rd/4th G. [[Cephalosporin]]||Cefotaxime||+
 
|-
 
|-
 
| ||Cefizoxime||+
 
| ||Cefizoxime||+
Line 78: Line 78:
 
| ||Cefepime||+
 
| ||Cefepime||+
 
|-
 
|-
| 1st G. Ceph||Cefadroxil||+
+
|Oral 1st G. [[Cephalosporin]]||Cefadroxil||+
 
|-
 
|-
 
| ||[[Cephalexin]]||+
 
| ||[[Cephalexin]]||+
 
|-
 
|-
| 2nd G. Ceph||Cefaclor/Loracarbef||+
+
|Oral  2nd G. [[Cephalosporin]]||Cefaclor/Loracarbef||+
 
|-
 
|-
 
| ||Cefproxil||+
 
| ||Cefproxil||+
Line 88: Line 88:
 
| ||Cefuroxime axetil||+
 
| ||Cefuroxime axetil||+
 
|-
 
|-
| 3rd G. Ceph||Cefixime||+
+
|Oral 3rd G. [[Cephalosporin]]||Cefixime||+
 
|-
 
|-
 
| ||Ceftibuten||+
 
| ||Ceftibuten||+
Line 94: Line 94:
 
| ||Cefpodox/Cefdinir/Cefditoren||+
 
| ||Cefpodox/Cefdinir/Cefditoren||+
 
|-
 
|-
| Aminoglycosides||Gentamicin||0
+
| [[Aminoglycosides[[||Gentamicin||0
 
|-
 
|-
 
| ||Tobramycin||0
 
| ||Tobramycin||0
Line 104: Line 104:
 
| ||Clindamycin||+
 
| ||Clindamycin||+
 
|-
 
|-
| Macrolides||Erythromycin||+/-
+
| [[Macrolides]]||Erythromycin||+/-
 
|-
 
|-
 
| ||Azithromycin||+/-
 
| ||Azithromycin||+/-

Revision as of 07:25, 4 March 2014

Background

Antibiotic Sensitivities[1]

Organisms ' Strep, Group A, B, C, G
Penicillins Penicillin G +
Penicillin V +
Anti-Staphylocccal Penicillins Methicillin +
Nafcillin/Oxacillin +
Cloxacillin/Diclox. +
Amino-Penicillins AMP/Amox +
Amox/Clav +
AMP-Sulb +
Anti-Pseudomonal Penicillins Ticarcillin +
Ticar-Clav +
Pip-Taxo +
Carbapenems Piperacillin +
Doripenem +
Ertapenem +
Imipenem +
Meropenem +
[[Aztreonam[[ 0
Fluroquinolones Ciprofloxacin +/-
Ofloxacin +/-
Pefloxacin 0
Levofloxacin +
Moxifloxacin +
Gemifloxacin +
Gatifloxacin +
1st G Cephalosporin Cefazolin +
2nd G. Cephalosporin Cefotetan +
Cefoxitin +
Cefuroxime +
3rd/4th G. Cephalosporin Cefotaxime +
Cefizoxime +
CefTRIAXone +
Ceftobiprole +
Ceftaroline +
CefTAZidime +
Cefepime +
Oral 1st G. Cephalosporin Cefadroxil +
Cephalexin +
Oral 2nd G. Cephalosporin Cefaclor/Loracarbef +
Cefproxil +
Cefuroxime axetil +
Oral 3rd G. Cephalosporin Cefixime +
Ceftibuten +
Cefpodox/Cefdinir/Cefditoren +
[[Aminoglycosides[[ Gentamicin 0
Tobramycin 0
Amikacin 0
Chloramphenicol +
Clindamycin +
Macrolides Erythromycin +/-
Azithromycin +/-
Clarithromycin +/-
Ketolide Telithromycin +
Tetracyclines Doxycycline +/-
Minocycline +
Glycylcycline Tigecycline +
Glyco/Lipoclycopeptides Vancomycin +
Teicoplanin +
Telavancin +
Fusidic Acid +/-
Trimethoprim +
TMP-SMX +
Urinary Agents Nitrofurantoin +
Fosfomycin
Other Rifampin +
Metronidazole 0
Quinupristin dalfoppristin +
Linezolid +
Daptomycin +
Colistimethate 0

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

Table Overview

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2010